REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
18/05/2026
Voltar para busca
Dado oficial do USPTO
X PARSOLEX PARTNER SOLUTIONS EXCELLENCE
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
36
Atualização mais recente
19/05/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
35, 45
Data de depósito
07/08/2019
Data de registro
18/05/2021
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
18/05/2021
Última transação
19/05/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
28/10/2019
Primeiro uso no comércio
28/10/2019
Código do desenho
3
Tipo de titular
03
Localização do titular
West Lafayette, IN, US
Examinador
BULLOFF, TOBY ELLEN
Unidade examinadora
N10
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of a stylized design comprised of two diagonal intersecting pill capsules forming a heart shaped arrow design on the left side and creating an "x" shape; the design element appears to the left of the wording "Parsolex"; centered underneath the design and "Parsolex" wording appears the wording "PARTNER SOLUTIONS EXCELLENCE".
Titulares e representantes
Titulares
Parsolex GMP Center, Inc.
Representantes
Jill J. Chalmers BRYAN CAVE LEIGHTON PAISNER LLP
Classificação técnica
Classes Nice
Classe 35Classe 45
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 35
Market assessment services; consulting servicesproviding market research and business analysis services in the pharmaceuticalmedical and healthcare fields; business consulting and planning services in the field of pharmaceuticalsmedicine and healthcare; business consulting and planning services in the field of the commercialization of pharmaceuticalsmedicines and healthcare products; business consulting services relating to product distributionoperations management serviceslogisticsreverse logisticssupply chainproduction systems and distribution solutions; consulting in the fields of sales methodssales managementsales improvement; business consultation; business administration consultation services; business operation consultation services; business consulting services in the field of pharmaceutical manufacturingpharmaceutical packagingdistribution; business consulting in the pharmaceutical productsmedical and healthcare industries; business consultingbusiness managementbusiness advisory services; marketing consulting services in the field of pharmaceuticalsmedicine and healthcare; business marketing consulting services; business consulting and management in the field of clinical trialsclinical data and regulatory submission management on behalf of medicalbiopharmaceutical and biotechnology companies to assist them with clinical researchclinical trials and applications for drug approval; branding and marketing services for others in the field of pharmaceuticalmedicalhealthcare industries; regulatory submission managementassisting others in preparing and filing applications for new drugs with governmental regulatory bodies; business consulting and management in the field of clinical trialsclinical data and regulatory submission management on behalf of medicalbiopharmaceutical and biotechnology companies to assist them with clinical researchclinical trials and applications for drug approval; advertising of custom services for pharmaceutical formulation designdesign of processes to transform inorganic and organic substancesscale-up of pharmaceutical manufacturing processespharmaceutical technology transfermanufacture of pharmaceuticalschemical and physical evaluation of pharmaceuticals for others; distributorship services of pharmaceutical and medical products for others; commercialization of pharmaceuticals and medical products for others
Classe 45
Consulting services in the field of regulatory compliance in the pharmaceuticalmedical and healthcare industries; regulatory services for otherstracking and monitoring regulatory requirements in the field of the pharmaceuticalmedicalhealthcare industries for regulatory compliance purposes
Publicações
Histórico de despachos e eventos da marca no USPTO.
36 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
18/05/2021
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
16/04/2021
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
15/04/2021
SUPC
STATEMENT OF USE PROCESSING COMPLETE
02/04/2021
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
01/04/2021
IUAF
USE AMENDMENT FILED
17/03/2021
EISU
TEAS STATEMENT OF USE RECEIVED
17/03/2021
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
22/09/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
28/07/2020
PUBO
PUBLISHED FOR OPPOSITION
28/07/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08/07/2020
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
24/06/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
16/06/2020
XAEC
EXAMINER'S AMENDMENT ENTERED
16/06/2020
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
16/06/2020
GNEA
EXAMINERS AMENDMENT E-MAILED
16/06/2020
CNEA
EXAMINERS AMENDMENT -WRITTEN
16/06/2020
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
10/06/2020
PBCR
WITHDRAWN FROM PUB - OG REVIEW QUERY
05/05/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
22/04/2020
XAEC
EXAMINER'S AMENDMENT ENTERED
22/04/2020
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
22/04/2020
GNEA
EXAMINERS AMENDMENT E-MAILED
22/04/2020
CNEA
EXAMINERS AMENDMENT -WRITTEN
22/04/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
16/04/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
16/04/2020
ALIE
ASSIGNED TO LIE
15/04/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/04/2020
GPRN
NOTIFICATION OF PRIORITY ACTION E-MAILED
31/10/2019
GPRA
PRIORITY ACTION E-MAILED
31/10/2019
CPRA
PRIORITY ACTION WRITTEN
31/10/2019
DOCK
ASSIGNED TO EXAMINER
16/10/2019
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
27/08/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
24/08/2019
NWAP
NEW APPLICATION ENTERED
10/08/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace X PARSOLEX PARTNER SOLUTIONS EXCELLENCE ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.